NCT03315026View on ClinicalTrials.gov

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 14, 2017

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Multiple MyelomaAL Amyloidosis
Interventions
DRUG

Siltuximab

Siltuximab at 11mg/kg will be administered as a 1-hour infusion on day -7 and day +21 (+/-2) after stem cell infusion.

BEHAVIORAL

The M.D. Anderson Symptom Inventory (MDASI)

assessments will be conducted at baseline (day -10 +/-3), day -2 (+/-1), , day +7 (+/-1 ), and day 30 (+/-3).

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER